Form 8-K · Current report
Edwards Lifesciences 8-K, filed Jul 23, 2026
- Filed
- CIK
- 0001099800
- Accession no.
- 0001099800-26-000038
Summary
Edwards Lifesciences reported second-quarter 2026 sales of $1.74 billion, up 13.6% year over year, with TAVR sales of $1.26 billion and TMTT sales of $195.9 million; adjusted EPS was $0.78. The company raised its 2026 constant-currency sales growth guidance for total company and TAVR and increased TMTT sales guidance, while reaffirming adjusted EPS guidance of $2.95 to $3.05.
Key points
- Q2 sales grew 13.6% to $1.74 billion, and constant-currency sales grew 12.5%.
- TAVR sales grew 11.3% to $1.26 billion, while TMTT sales were $195.9 million, up 47.3%.
- Edwards increased 2026 total company constant-currency sales growth guidance to 10%-11% from 9%-11%, TAVR guidance to 8%-9%, and TMTT sales guidance to $760-$780 million.
- CMS is expected to issue a final decision memo on the National Coverage Determination for TAVR in September, and Edwards expects Q4 approvals for the PASCAL tricuspid indication and next-generation PASCAL with Capture Clarity in the U.S. and Europe.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On July 23, 2026, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the second quarter of 2026. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended. Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated July 23, 2026, reporting Edwards’ financial results for the second quarter of 2026. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.